Literature DB >> 24172100

Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group.

Mikio Mikami1, Yoichi Aoki, Masaru Sakamoto, Muneaki Shimada, Nobuhiro Takeshima, Hisaya Fujiwara, Takashi Matsumoto, Tunekazu Kita, Ken Takizawa.   

Abstract

OBJECTIVE: The objective of this study was to determine the current operative principle of uterine cervical cancer of stages Ia2, Ib1, and IIa1 (International Federation of Gynecology and Obstetrics) in Japan by surveying member institutions of the Japanese Gynecologic Oncology Group (JGOG).
METHODS: We conducted a survey to assess the current operative principle, including indications and treatment, at all 199 active member institutions of the JGOG.
RESULTS: A total of 166 institutions (83.4%) responded to the survey. For Ia2 squamous cell carcinoma without the need to preserve fertility, modified radical hysterectomy was performed, and lymph node dissection was done in about 85%. At 60% of JGOG institutions, it was considered that less invasive procedures might be suitable. At the majority of JGOG institutions, radical surgery and lymph node dissection were considered necessary for stages Ib1 and IIa1 squamous cell carcinoma, with 70% considering that less invasive procedures might not be suitable.
CONCLUSIONS: This survey provides information regarding the current status of surgical principle for uterine cervical cancer (stages Ia2, Ib1, and IIa1) in Japan.

Entities:  

Mesh:

Year:  2013        PMID: 24172100     DOI: 10.1097/IGC.0000000000000005

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients.

Authors:  Naoki Horikawa; Tsukasa Baba; Noriomi Matsumura; Ryusuke Murakami; Kaoru Abiko; Junzo Hamanishi; Ken Yamaguchi; Masafumi Koshiyama; Yumiko Yoshioka; Ikuo Konishi
Journal:  BMC Cancer       Date:  2015-10-19       Impact factor: 4.430

2.  Identifying a low-risk group for parametrial involvement in microscopic Stage IB1 cervical cancer using criteria from ongoing studies and a new MRI criterion.

Authors:  Jung-Yun Lee; Jina Youm; Jae-Weon Kim; Jeong Yeon Cho; Min A Kim; Tae Hun Kim; Dong Hoon Suh; Myong Cheol Lim; Noh Hyun Park; Yong-Sang Song
Journal:  BMC Cancer       Date:  2015-03-22       Impact factor: 4.430

3.  Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis.

Authors:  Munetaka Takekuma; Mototsugu Shimokawa; Shin Nishio; Hideo Omi; Tsutomu Tabata; Yuji Takei; Kaei Nasu; Yoshiyuki Takahashi; Shinji Toyota; Yoshikazu Ichikawa; Atsushi Arakawa; Fuminori Ito; Hiroshi Tsubamoto; Taisuke Mori; Yasuyuki Hirashima; Kimihiko Ito
Journal:  Cancer Sci       Date:  2018-04-15       Impact factor: 6.716

4.  Clinical experience of pelvic radiotherapy or chemoradiotherapy for postoperative uterine cervical cancer using intensity-modulated radiation therapy.

Authors:  Takaya Yamamoto; Rei Umezawa; Hideki Tokunaga; Masaki Kubozono; Maiko Kozumi; Noriyoshi Takahashi; Haruo Matsushita; Noriyuki Kadoya; Kengo Ito; Kiyokazu Sato; Keita Tsuji; Muneaki Shimada; Keiichi Jingu
Journal:  J Radiat Res       Date:  2020-05-22       Impact factor: 2.724

5.  Tailoring Pelvic Lymphadenectomy for Patients with Stage IA2, IB1, and IIA1 Uterine Cervical Cancer.

Authors:  Juan Zhou; Jing Ran; Zhen-Yu He; Song Quan; Qiong-Hua Chen; San-Gang Wu; Jia-Yuan Sun
Journal:  J Cancer       Date:  2015-02-25       Impact factor: 4.207

6.  Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.

Authors:  Yuji Ikeda; Akiko Furusawa; Ryo Kitagawa; Aya Tokinaga; Fuminori Ito; Masayo Ukita; Hidetaka Nomura; Wataru Yamagami; Hiroshi Tanabe; Mikio Mikami; Nobuhiro Takeshima; Nobuo Yaegashi
Journal:  J Gynecol Oncol       Date:  2016-05       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.